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Introduction
Addition of rituximab to induction chemotherapy in 
DLBCL has improved prognosis, specially bcl2 positive 
and non-germinal center subtype of DLBCL (Fenske et 
al., 2009). Response rates with single agent rituximab 
in DLBCL at initial diagnosis is approximately 30-35% 
(Davis et al., 1999; Kewalramani et al., 2004). Combination 
of rituximab with chemotherapy has improved complete 
response rates to 75%-80% (Gisselbrecht et al., 2010). 
Unfortunately, 30-40 % patients relapse after complete 
response and 10% are refractory to standard anthracycline 
based regimen ( Raut and Chakrabarti, 2014). At relapse, 
retreatment with chemo immunotherapy shows a response 
rate of 55% when compared to 28% when treated with 
regimens without rituximab (Raut and Chakrabarti, 2014; 
Jiang et al., 2013). 
Abstract
Introduction: Down regulation of CD20 expression has been reported in diffuse large B cell lymphoma (DLBCL)). 
Therefore, it is important to determine whether chemotherapy with rituximab induces CD20 down regulation and effects 
survival. Objectives: To determine the incidence of down regulation of CD20 expression in relapsed DLBCL after 
treatment with rituximab and to compare outcomes and assess pattern of relapse between CD20 negative and CD20 
positive cases. Methodology: We retrospectively reviewed patients with relapsed DLBCL who received rituximab in 
the first line setting at Aga Khan University Hospital between January 2007 and December 2014. Data were recorded 
on predesigned questionnaires, with variables including demographics, details regarding date of diagnosis and relapse, 
histology, staging, international prognostic index, treatment and outcomes at initial diagnosis and at relapse. The Chi 
square test was applied to determine statistical significance between categorical variables. Survival curves were generated 
by the Kaplan–Meier method. Results: A total of 54 patients with relapsed DLBCL were included in our study, 38 (70 
%) males and 16(30%) females. Some 23 (43%) patients were at stage IV at the time of diagnosis and 34 (63%) had B 
symptoms. The most frequent R-IPI at diagnosis was II in 24 (44%) patients. Only 6 (11%) did not show CD20 expression 
on re-biopsy for relapsed/refractory disease, 2 with CD20 negative DLBCL responding to second line chemotherapy. 
A complete response after salvage chemotherapy was noted in 16 (29.6%) cases with relapsed/refractory DLBCL. 
Seven (13%) patients underwent an autologous bone marrow transplant as consolidation after second line treatment. 
Median overall survival was 18 months in CD20 positive vs. 13 months in CD20 negative patients. Conclusion: This 
study demonstrated that a small percentage of patients treated with rituximab lose their CD20 expression at the time 
of relapse. However, it is unclear whether this is associated with an inferior outcome.
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RESEARCH ARTICLE
Cd20 Expression and Effects on Outcome of Relapsed/
Refractory Diffuse Large B Cell Lymphoma after Treatment 
with Rituximab
Afshan Asghar Rasheed1, Adeel Samad2, Ahmed Raheem1, Samina Ismail Hirani2, 
Munira Shabbir- Moosajee1*
A decrease in response to rituximab at relapse is 
likely secondary to drug resistance, however, the exact 
mechanisms are not clearly defined (Rezvani and Maloney, 
2011). Possible mechanisms are loss of CD20 expression, 
inflection of receptor, alteration in signaling pathways 
and decreased apoptotic and complement activity In low 
grade lymphoma, after rituximab exposure, it has been 
observed that loss of CD20 expression lead to conversion 
of low grade lymphoma to high grade lymphoma and 
inferior survival (Gisselbrecht et al., 2010). However, 
there is sparse data on clinical outcomes of CD20 
negative relapsed/ refractory DLBCL with prior rituximab 
exposure. We aim to determine the clinical features and 
prognosis of DLBCL after loss of CD20 expression. 
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Materials and Methods
This is a retrospective cohort study. After exemption 
approval from hospital ethical review committee 
medical records of patients with relapsed/refractory 
DLBCL who received treatment at Aga Khan University 
hospital (AKUH) were reviewed from January 2007 and 
December 2014. We included only those patients who had 
received rituximab as part of the first line therapy and had 
pathological assessment at the time of relapse. Patients 
who did not have adequate biopsy specimen for review 
at the time of relapse and those who didn’t receive second 
line treatment and followup at AKUH were excluded 
from the study.
Primary objective of the study was to determine the 
incidence of CD20 expression in patients with relapsed 
DLBCL who were previously exposed to rituximab. The 
secondary objectives included disease characteristics, 
disease free survival and overall survival of CD20 positive 
and CD20 negative relapsed DLBCL. For our analysis 
disease free survival was defined as any recurrence after 
completion of definitive treatment and overall survival 
was defined as time from initial diagnosis until death from 
any cause. Patients were followed from the time of initial 
diagnosis till last follow up if alive or till death.
Statistical analysis: SPSS version 19 was used for 
statistical analysis. Descriptive statistics were calculated 
with the help of mean standard deviation and for 
categorical variables, frequencies and percentages were 
used. Chi square test was applied to determine statistical 
significance between categorical variables. Survival 
curves were calculated by Kaplan–Meier curve. P<0.05 
was considered to be statistically significant and P<0.1 
showed trend toward significance.
Results
Patient characteristics at initial diagnosis
Fifty four patients were included in the analysis. 
Among them, 38 (70%) were male and 16 (30%) were 
female. The mean age at diagnosis was 55.3+/-16.7 years 
(range, 22-91 years). 34 (63%) patients presented with B 
symptoms. Most common stage was stage IV in 23(43%) 
patients. 70% of the patients had low- high intermediate 
prognosis as classified by Revised International Prognostic 
Index (R-IPI). (Table 1)
The most frequently prescribed first line chemo 
regimen was R-CHOP in 44 (81.5%) patients. 8 (14.8%) 
patients received R-CVP and 2 (3.7%) patients were 
treated with R-EPOCH. 26(48%) patients also received 
intrathecal chemotherapy for central nervous system 
prophylaxis. 26(48.1%) showed complete response at end 
of treatment evaluation. Among 26 patients who showed 
complete response, 17(31.4%) had low RIPI.
Patient characteristics at relapse
26 patients relapsed after first line therapy. Median 
time interval between last dose of rituximab and re-biopsy 
at the time of radiographic disease relapse was 11(6-96) 
months. At relapse, 2 (3.7%) patients were CD20 negative 
and 24 patients remained CD20 positive as determined by 
immunohistochemistry (IHC). PAX-5 was then performed 
on CD20 negative samples and found to be positive in 1/2 
patients. There was no statistically significant difference in 
the expression on ki67 between the biopsy specimens taken 
at initial diagnosis and relapse. The most common site of 
relapse in CD20 negative patients was gastrointestinal tract 
in both patients. In CD20 positive patients, lymph nodal 
relapse was most frequently documented in 11 (46%) 
patients followed by gastrointestinal tract in 4(16.6%) 
patients. DHAP/R-DHAP was prescribed in 11(45.6%), 
ICE/R-ICE in 6 (25%) and others in 7(29.4%) patients. 
Complete response (CR) to salvage chemotherapy was 
documented by imaging studies in 13 (50%) patients out 
of which 12 patients were CD20 positive and 1 patient was 
CD 20 negative. DHAP/RDHAP was the was the most 
successful regimen, with a CR documented in 8/13(61%) 
(P-0.11). 5 patients underwent high dose chemotherapy 
with autologous stem cell bone marrow rescue as 
consolidation therapy in second complete remission. 
4 patients after bone marrow transplant alive and disease 
free till date. Comparison of CD20 positive and CD20 
negative patients have been described in Table 2.
Characteristics of patient’s refractory to first line therapy
2 8 ( 5 2 % )  w e r e  r e f r a c t o r y  t o  f i r s t  l i n e 
chemo-immunotherapy. 19(68%) of the patients were 
male. Most of the patients had stage III/IV (57%) at 
Age Groups <= 50Years 22(40.7%)
>50 Years 32(59.3%)
Gender Male 38 (70%)
Female 16 (30%)
B Symptoms Yes 34 (63%)
No 20 (37%)
Stage Stage I / II 3 (06%) /17 (32%)
Stage III / IV 11 (20%)/23 (43%)
RIPI RIPI I / II 11 (20%)/24 (44%)
RIPI III / IV 14 (26%)/5 (09%)
Table 1. Patient Characteristics at Initial Diagnosis
SD, standard deviation; RIPI, rituximab International Prognostic Index
Figure 1. Overall Survival of Patients According to 
CD20 Expression at Relapse
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17.5 months in CD20 positive vs. 13 months in CD20 
negative patients (95% CI: 0.9520 to 1.740,p-0.33). 
However, patients’ who achieved CR and then went on 
to receive an autologous stem cell transplant, the OS was 
increased to 62 months (Figure 2). 
Discussion
DLBCL with low/ absent CD20 expression at initial 
diagnosis is a rare phenomenon and has been shown to 
behave aggressively (Vega et al., 2005). Li et al., (2012) 
studied 28 patients with CD20 negative DLBCL and his 
analysis revealed that this cohort of patients had a more 
aggressive phenotype and an inferior survival then CD20 
positive DLBCL counterparts. Loss of CD20 expression 
has been observed more frequently in non-GC type of 
DLBCL (Tsutsumi et al., 2016). The outcome of patients 
with de novo CD20 negative DLBCL is reported to be 
inferior to the CD20 positive DLBCL (Hiraga et al., 
2009). The effect of loss of CD20 expression in relapsed/
refractory DLBCL is unclear. We report the results of the 
largest case series describing the incidence and outcome 
of patients with CD20 negative DLBCL after treatment 
with rituximab.
There are several mechanisms that have been proposed 
to explain loss of CD20 expression in lymphoma cells 
that might lead to resistance to rituximab. Mechanism 
of resistance to rituximab beside CD20 receptor loss 
are separation of CD20 rituximab complexes and 
neoplasm micro-environment (Czuczman et al., 2008). 
Possible molecular pathways that leads to resistance to 
rituximab is down regulation of NF-κB pathway, PI3K/
AKT pathway and overexpression of anti-apoptotic gene 
products (e.g. Bcl2)/ There is preliminary data of Bcl2 
pan inhibitor (Oblimersem) that showed clinical response 
in heavily treated lymphoma patients (Smith, 2003) to 
overcome NF-κB pathway, trials including combination 
of rituximab and bortezomib trials are ongoing as salvage 
treatment in B cell lymphomas (Bonavida, 2014). In 
Shimizu et al., (2009) Study, treatment with valproic 
acid and romidepsin(HDAC inhibitor) augmented the 
expression of CD20 and increased rituximab-mediated 
time of diagnosis and RIPI of III/IV (53%). The interval 
between last dose of rituximab and biopsy was 2 months. 
On re-biopsy 24(86%) remained CD20 positive and 
4(14.3%) patients with refractory disease lost CD20 
expression (p-0.67). These patients went on to receive 
second line chemotherapy and DHAP/R-DHAP remained 
the preferred choice of therapy. 3 (11%) showed CR to 
salvage chemotherapy and 9(32%) showed stable disease 
(p-0.001). Out of 4 patients who were CD20 negative, 
showed only 1 patient demonstrated CR to salvage 
chemotherapy. Among 3 patients who achieved complete 
response after second line chemotherapy, 2 underwent 
bone marrow transplant. 1 patient passed away in a year 
after bone marrow transplant secondary with relapsed 
disease. 1 patient is alive till date.
Outcome
Among patients who achieved CR, their time to 
progression was 15 months in CD20 positive vs.10 months 
in CD20 negative cohort (95%CI 8.95-21.05, p<0.05). 
The median disease free survival was 12 months vs. 9 
months in the CD20 positive and CD20 negative patients 
respectively (95%CI: 9.455-14.545, p-0.192). Median 
overall survival was 17 months for the entire cohort (95% 





Mean age 55.3 53.6
Gender
   Males 29(60%) 5(83.3%)
   Females 19(40%) 1(16.6)
RIPI II/III II/III
Initial regimen
   R-CHOP 39(69.6%) 5(83.3%)
   RCVP 7(13%) 1(16.7%)
   REPOCH 2(3.7%)
Response to First line treatment
   CR 26(48%) 2(33%)
   Relapsed 24(50%) 2(33%)
   Refractory 24(50%) 4(66.6%)
Salvage chemo 
   RDHAP/DHAP 8(33.3%) 3(50%)
   ICE 5(21%) 1(16.6%)
   Others 4(16.6%) 2(33.3%)
Site of relapse
   Lymph nodes 11(46%) 0
   GIT 4(14.6%) 2(100%)
Response to salvage Chemo 
   Complete response 12(50%) 2(33%)
   Refractory 28(44.4%) 4(14.3%)
   Median DFS(Months) 12 9
   Median OS (Months) 17.5 13
Table 2. Comparison of Patients According to CD20 
Expression 
Figure 2. Over all survival of patients underwent bone 
marrow transplant vs non transplant patients
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CDC cytotoxicity. It has been shown, that CD20 mRNA 
expression was significantly low in CD20 negative when 
compared to CD20 positive lymphoma cells (Hiraga et 
al., 2009). Interesting, when treated with 5’ azacitdine, 
CD20 mRNA expression was restored in three days 
(Tsutsumi et al., 2016). This suggests that prior treatment 
with rituximab can cause epigenetic down regulation of 
the CD20 gene and hence resulting in decrease protein 
expression (Wada et al., 2009). CD20 mutations may also 
have a role, albeit, controversial (Johnson et al., 2009). 
C terminal deletion of the CD20 molecule has been shown 
to contribute to decreased CD20 expression in patients 
with prior exposure to rituximab (Tsai et al., 2012). D20 
splice variants which result in the loss of the binding 
epitope have been shown to cause rituximab resistant, 
but this finding has not been validated (Smal et al., 2013).
The incidence of loss of CD20 expression is varied. 
Naoki Wada et al., (2009) reported that, 4(19%) of the 
21 cases showed loss of CD20 negative expression 
after rituximab containing treatment. Kennedy et al., 
(2002) reported CD20 negativity in 6/10(60%) patients 
with relapsed DLBCL. Hiagra et al., (2009) reviewed 
data of 124 patients with relapsed DLBC .19 of 124 
were re-biopsied at relapse and 5/19(26%) lost CD20 
expression (Hiraga et al., 2009). We observed loss of 
CD20 expression in 11% of patients. We hypothesize that 
there are multiple factors contributing to the variability of 
the reported difference in loss of CD20 expression. One 
major contributing factor is that very few patients undergo 
a repeat biopsy at relapse. Indeed, as reported in by Hiraga 
et al and other studies, only approximately 15% patients 
undergo histopathological diagnosis at relapse (Tsai et 
al., 2012). Therefore, it is postulated that this incidence 
is likely underreported. 
Another explanation is that the laboratory tests to check 
for CD20 expression were different in the reported studies. 
Immuno- histochemical analysis and flow cytometry are 
the two methods used, however, immunohistochemistry 
appears to be method of choice (Tokunaga et al., 2014). 
Chu et al., (2006) demonstrated that in the case of loss 
of CD20 expression 88% and 81% expressed Pax5 and 
CD79a. In the rare instance that these routine markers 
are not expressed, OCT. 2 and BOB. 1 can be used to 
determine lineage specification (Small et al., 2013). Flow 
cytometry identify surface receptors; however, this can be 
masked by rituximab (Jilani et al., 2003). It also is known 
that circulating rituximab can be detected in the peripheral 
blood even 6 months post Rituximab treatment. Therefore, 
flow cytometry is not considered to be a sensitive test to 
determine lineage (Berinstein et al., 1998). Given these 
findings and the relatively ease and reproducibility of 
IHC, it is now the preferred method to determine lineage 
specification for inclusion in clinical trials ( Jiang et al., 
2013; Johnson et al, 2009). 
Maeshima et al., (2008) suggested that biopsy site 
(bone marrow vs. non-bone marrow) might change 
the CD20 expression. Foran et al., (2001) interesting 
results of their cohort of 25 patients with relapsed 
non-Hodgkin’s lymphoma. While bone marrow infiltration 
with lymphoma of 6 out of 24 patients was CD20 negative, 
lymph node biopsy remained to be CD20 positive in all 
patients. This discrepancy, however, did not infer an 
inferior prognosis. Therefore, it might be important to 
determine CD20 expression by immunophenotyping both 
the systemic and involved bone marrow biopsy specimens. 
However, clinical significance of discrepancy of CD20 
expression is not well understood and should not dissuade 
use of rituximab. 
It is also suggested that CD20 negative patients 
present with more extra nodal disease (23.8% vs. 9.5%) 
and bone involvement (9.5% vs. 0%) when compared 
to CD20 positive NHL ( Li et al., 2012). Our study also 
mimics these findings with gastrointestinal tract as the 
most frequent site of relapse in CD20 negative patients 
while nodal relapse (46%) was frequently documented in 
CD20 positive patients. 
Response to second line chemotherapy in relapsed 
DLBCL has been reported as 50% in literature 
(Alvaro-Naranjo et al., 2003). Our study mirrors this 
finding with 50% showing complete response to salvage 
chemotherapy. In our experience, CR rates with DHAP/
RDHAP in relapse (61%) and refractory (11%) patients 
were higher than other regimens. We also observed that 
re-treatment with rituximab in the second line setting 
produced better response rates in the relapsed rather than 
the refractory setting. In our study, 54% patients at relapse 
received rituximab containing salvage regimen and 50% 
of them showed complete response. Among refractory 
patients who received rituximab with chemotherapy as 
second line, only 7% showed response. This is consistent 
with question raised in CORAL study, whether patients 
refractory to rituximab containing induction regimen 
can be retreated with rituximab (Friedberg, 2011). 
An interesting finding in our study was that the loss of 
CD20 expression was more frequently seen in the patients’ 
refractory to first line therapy (67% vs. 33%).
Our study has some limitations as this is a retrospective 
study. Even though, biopsy samples were available to be 
reviewed, we could not perform additional IHC analysis 
for further classification according to its cell of origin. 
This limits us in reporting detailed immunophenotype of 
the cohort. The strength of our study is that we included 
a relatively homogenous group of patients. Only those 
patients that had a biopsy at diagnosis and relapse at our 
institution were included in the study. This allowed us 
to reconfirm the CD20 expression for inclusion in the 
analysis. Additionally, most of the reported case series 
have included all subtypes of NHL. Our cohort was 
exclusively of patients with relapsed/refractory DLBCL. 
Therefore, the effect in outcome with regards to loss of 
CD20 expression in this subset of patients is likely to be 
clinically valid. 
In conclusion, prognosis of patients in DLBCL 
depends on response to induction chemotherapy. 
Incidence of CD20 loss after rituximab therapy is low 
but appears to be more common in the refractory rather 
than relapsed setting. Patients who respond to second 
line therapy have a better outcome which is irrespective 
of CD20 expression. It is important that all patients with 
relapsed/refractory DLBCL have repeat biopsies at the 
time of progression. This will aid in better understanding 
of the cellular and molecular characteristics and tailor 
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treatment and develop novel therapeutic agents. 
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